Participant flow

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · Source last updated 2026-08-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

   id

   FG000

   title

   Treatment A

2. description

   Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

   id

   FG001

   title

   Treatment B

3. description

   Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle

   id

   FG002

   title

   Treatment C

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         62

      2. group Id

         FG001

         num Subjects

         13

      3. group Id

         FG002

         num Subjects

         84

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         13

      type

      Participant withdrew consent

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      type

      Not reported

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         1

      type

      Lost to Follow-up

   5. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         11

      type

      Other reasons

   6. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         8

      type

      Participants did not start treatment period

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         323

      2. group Id

         FG001

         num Subjects

         50

      3. group Id

         FG002

         num Subjects

         328

      comment

      Started=Randomized

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         320

      2. group Id

         FG001

         num Subjects

         50

      3. group Id

         FG002

         num Subjects

         320

      comment

      Treated=Started treatment period

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         242

      2. group Id

         FG001

         num Subjects

         34

      3. group Id

         FG002

         num Subjects

         210

      comment

      Completed=Continuing in the Study

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         81

      2. group Id

         FG001

         num Subjects

         16

      3. group Id

         FG002

         num Subjects

         118

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

701 participants randomized and 690 treated.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice